Get the Stockscreener App
1.49
7.97%
0.11
Compass Therapeutics Inc stock is traded at $1.49, with a volume of 536.34K.
It is up +7.97% in the last 24 hours and down -18.58% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
See More
Previous Close:
$1.38
Open:
$1.4
24h Volume:
536.34K
Relative Volume:
1.12
Market Cap:
$200.88M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-4.027
EPS:
-0.37
Net Cash Flow:
$-42.28M
1W Performance:
+7.97%
1M Performance:
-18.58%
6M Performance:
-4.49%
1Y Performance:
-13.37%
1-Day Range:
$1.36
$1.525
1-Week Range:
$1.27
$1.525
52-Week Range:
$0.765
$2.34
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CMPX | 1.49 | 200.88M | 0 | -45.44M | -42.28M | -0.37 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX) - Yahoo Canada Finance
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
Compass Therapeutics (NASDAQ:CMPX) Cut to Market Perform at Leerink Partners - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock - MSN
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - MSN
Leerink Partnrs Downgrades Compass Therapeutics (NASDAQ:CMPX) to Hold - MarketBeat
DelphX announces non-brokered unit private placement - MSN
U.S. STOCKS FuelCell Energy, consumer goods stocks, Rocket Companies - XM
Compass Therapeutics (NASDAQ:CMPX) Downgraded to "Market Perform" Rating by Leerink Partners - MarketBeat
Wedbush Expects Higher Earnings for Compass Therapeutics - MarketBeat
What is HC Wainwright's Forecast for CMPX FY2024 Earnings? - MarketBeat
Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC's Strategic Reduction in Compass Thera - GuruFocus.com
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment - Benzinga
What is HC Wainwright's Estimate for CMPX FY2028 Earnings? - MarketBeat
Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress - TipRanks
Compass Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Compass Therapeutics (CMPX) to Present at Stifel and Jefferies Healthcare Conferences | CMPX Stock News - StockTitan
PD-1 and PD-L1 Inhibitors Market Projected to Surge, Reaching USD XX Billion by 2031 As Revealed In New Report - WhaTech
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Key Trial Progress, $135M Cash Runway Through 2027 | CMPX Stock News - StockTitan
HC Wainwright Reaffirms "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics Presents Novel Biomarker Data Related - GlobeNewswire
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Treatment Resistant Depression Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Treatment Resistant Depression Pipeline Therapeutics, - openPR
Compass delays anticipated psilocybin readout, cuts staff - Yahoo Finance
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024 - MD Magazine
Treatment Resistant Depression Clinical Trials 2024: FDA - openPR
Biotech stock tumbles after unexplained 1,446% gain - MSN
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Financial Snapshot: Analyzing Compass Therapeutics Inc (CMPX)’s Key Ratio Metrics - The Dwinnex
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - Investing News Network
CMPX’s 2023 Market Dance: Up 26.92% – Time to Invest? - The InvestChronicle
Renaissance Technologies LLC Decreases Position in Imperial Petroleum Inc. (NASDAQ:IMPP) - Defense World
JetBlue Airways (NASDAQ:JBLU) Raised to “Sell” at StockNews.com - Defense World
Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA - openPR
Silicon Laboratories Inc. (NASDAQ:SLAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Compass Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Compass Therapeutics Inc (CMPX)’s stock price range in the last year - US Post News
American Century Companies Inc. Cuts Stake in Compass Minerals International, Inc. (NYSE:CMP) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.7% in September - MarketBeat
Rhumbline Advisers Takes Position in LINKBANCORP, Inc. (NASDAQ:LNKB) - Defense World
Rhumbline Advisers Trims Holdings in Pembina Pipeline Co. (NYSE:PBA) - Defense World
Analyzing Neurocrine Biosciences (NASDAQ:NBIX) and Compass Therapeutics (NASDAQ:CMPX) - Defense World
NSK (OTCMKTS:NPSKY) Stock Price Passes Above 50-Day Moving Average of $10.02 - Defense World
PCM Fund Inc. (NYSE:PCM) Short Interest Down 36.3% in September - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):